vTv Therapeutics (NASDAQ:VTVT) Downgraded to Hold at ValuEngine

vTv Therapeutics (NASDAQ:VTVT) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, June 3rd, ValuEngine reports.

A number of other equities research analysts have also commented on the stock. Northland Securities upgraded shares of vTv Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, May 6th. HC Wainwright began coverage on shares of vTv Therapeutics in a research report on Thursday, May 30th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd.

vTv Therapeutics stock traded up $0.06 during mid-day trading on Monday, hitting $1.41. 108,428 shares of the company traded hands, compared to its average volume of 911,131. The firm has a market capitalization of $69.60 million, a PE ratio of -2.04 and a beta of -3.70. vTv Therapeutics has a one year low of $0.68 and a one year high of $6.09. The business’s fifty day moving average price is $1.53.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($0.26) EPS for the quarter. The company had revenue of $0.92 million for the quarter. As a group, sell-side analysts anticipate that vTv Therapeutics will post -0.59 earnings per share for the current fiscal year.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman bought 1,212,121 shares of vTv Therapeutics stock in a transaction dated Tuesday, June 25th. The shares were purchased at an average cost of $1.65 per share, with a total value of $1,999,999.65. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Ronald O. Perelman bought 1,358,698 shares of vTv Therapeutics stock in a transaction dated Wednesday, May 15th. The stock was acquired at an average cost of $1.84 per share, for a total transaction of $2,500,004.32. The disclosure for this purchase can be found here. 1.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. Wedbush Securities Inc. bought a new position in vTv Therapeutics during the 1st quarter valued at about $30,000. Barclays PLC lifted its stake in vTv Therapeutics by 366.7% during the 4th quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 22,000 shares during the period. Finally, D. E. Shaw & Co. Inc. bought a new position in vTv Therapeutics during the 4th quarter valued at about $186,000. Institutional investors own 3.94% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Read More: Google Finance Portfolio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply